These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9138111)

  • 1. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase.
    Marcoval J; Moreno A; Graells J; Vidal A; Escribà JM; Garcia-Ramírez M; Fabra A
    J Cutan Pathol; 1997 Apr; 24(4):212-8. PubMed ID: 9138111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.
    Straume O; Akslen LA
    Am J Pathol; 2001 Jul; 159(1):223-35. PubMed ID: 11438469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression.
    Gorski DH; Leal AD; Goydos JS
    J Am Coll Surg; 2003 Sep; 197(3):408-18. PubMed ID: 12946796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression of vascular endothelial growth factor in metastatic melanoma.
    Salven P; Heikkilä P; Joensuu H
    Br J Cancer; 1997; 76(7):930-4. PubMed ID: 9328154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
    Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
    Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.
    Barnhill RL; Levy MA
    Am J Pathol; 1993 Jul; 143(1):99-104. PubMed ID: 7686347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis.
    Erhard H; Rietveld FJ; van Altena MC; Bröcker EB; Ruiter DJ; de Waal RM
    Melanoma Res; 1997 Aug; 7 Suppl 2():S19-26. PubMed ID: 9578413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma.
    Barnhill RL; Fandrey K; Levy MA; Mihm MC; Hyman B
    Lab Invest; 1992 Sep; 67(3):331-7. PubMed ID: 1383607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma.
    Pritchard-Jones RO; Dunn DB; Qiu Y; Varey AH; Orlando A; Rigby H; Harper SJ; Bates DO
    Br J Cancer; 2007 Jul; 97(2):223-30. PubMed ID: 17595666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
    Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
    Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor.
    Tóth-Jakatics R; Jimi S; Takebayashi S; Kawamoto N
    Hum Pathol; 2000 Aug; 31(8):955-60. PubMed ID: 10987256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma.
    Goydos JS; Gorski DH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5962-7. PubMed ID: 14676121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiogenesis and tumor progression in melanoma].
    Vacca A; Ria R; Ribatti D; Bruno M; Dammacco F
    Recenti Prog Med; 2000 Nov; 91(11):581-7. PubMed ID: 11125952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
    Špirić Z; Eri Ž; Erić M
    Int J Surg Pathol; 2015 Dec; 23(8):629-37. PubMed ID: 25911567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
    Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
    J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
    Brychtova S; Bezdekova M; Brychta T; Tichy M
    Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma.
    Clarijs R; Schalkwijk L; Ruiter DJ; de Waal RM
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1422-8. PubMed ID: 11381041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thin Melanoma: A Generic Term Including Four Histological Subtypes of Cutaneous Melanoma.
    Roncati L; Pusiol T; Piscioli F
    Acta Dermatovenerol Croat; 2016 Dec; 24(4):169-174. PubMed ID: 28128089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.
    Boyd SR; Tan DS; de Souza L; Neale MH; Myatt NE; Alexander RA; Robb M; Hungerford JL; Cree IA
    Br J Ophthalmol; 2002 Apr; 86(4):440-7. PubMed ID: 11914215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.